Review article · 2013

Current research in empirical therapy for febrile neutropenia in cancer patients: what should be necessary and what is going on

Elio Castagnola, Małgorzata Mikulska, Paola Barabino, Ines Lorenzi, Riccardo Haupt, Claudio Viscoli

Expert Opinion on Emerging Drugs, 18(3), 263–278 · Published 19 June 2013 · DOI 10.1517/14728214.2013.809419

View at the publisherCite this paper

In brief

“Current research in empirical therapy for febrile neutropenia in cancer patients: what should be necessary and what is going on” is a 2013 review article by Elio Castagnola and 5 co-authors, published in Expert Opinion on Emerging Drugs. OpenAlex counts 12 citations as of 19 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
12
Most cited in
2015 (3)
Field-weighted impact
0.20
References
128
Authors
6

Abstract

INTRODUCTION: Fever is an important complication in neutropenic patients and standard of care calls for empirical broad-spectrum antibiotics, followed by 'empirical' antifungal therapy in persisting fever. Emergence of infections due to resistant bacteria, especially Gram-negatives, and usefulness of empirical antifungal therapy represent the major concerns in this field. AREAS COVERED: Clinical trials registered in 5… Read the full abstract at the publisher.

Excerpt. This paper is not open access.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Castagnola, E., Mikulska, M., Barabino, P., Lorenzi, I., Haupt, R., & Viscoli, C. (2013). Current research in empirical therapy for febrile neutropenia in cancer patients: what should be necessary and what is going on. Expert Opinion on Emerging Drugs, 18(3), 263–278. https://doi.org/10.1517/14728214.2013.809419

MLA 9

Castagnola, Elio, et al. “Current research in empirical therapy for febrile neutropenia in cancer patients: what should be necessary and what is going on.” Expert Opinion on Emerging Drugs, vol. 18, no. 3, 2013, pp. 263–278. https://doi.org/10.1517/14728214.2013.809419.

Chicago

Castagnola, Elio, Małgorzata Mikulska, Paola Barabino, Ines Lorenzi, Riccardo Haupt, and Claudio Viscoli. 2013. “Current research in empirical therapy for febrile neutropenia in cancer patients: what should be necessary and what is going on.” Expert Opinion on Emerging Drugs 18 (3): 263–278. https://doi.org/10.1517/14728214.2013.809419.

Harvard

Castagnola, E. et al. (2013) ‘Current research in empirical therapy for febrile neutropenia in cancer patients: what should be necessary and what is going on’, Expert Opinion on Emerging Drugs, 18(3), pp. 263–278. doi:10.1517/14728214.2013.809419.

IEEE

E. Castagnola, M. Mikulska, P. Barabino, I. Lorenzi, R. Haupt, and C. Viscoli, “Current research in empirical therapy for febrile neutropenia in cancer patients: what should be necessary and what is going on,” Expert Opinion on Emerging Drugs, vol. 18, no. 3, pp. 263–278, 2013, doi: 10.1517/14728214.2013.809419.

BibTeX

@article{castagnola2013current,
  title     = {{Current research in empirical therapy for febrile neutropenia in cancer patients: what should be necessary and what is going on}},
  author    = {Castagnola, Elio and Mikulska, Małgorzata and Barabino, Paola and Lorenzi, Ines and Haupt, Riccardo and Viscoli, Claudio},
  journal   = {Expert Opinion on Emerging Drugs},
  year      = {2013},
  volume    = {18},
  number    = {3},
  pages     = {263--278},
  doi       = {10.1517/14728214.2013.809419},
  url       = {https://doi.org/10.1517/14728214.2013.809419}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201411
201533
201611
201733
201811
202011
202211
202311

Its field-weighted citation impact is 0.20: it has been cited 0.20 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections

  • febrile neutropenia
  • cancer patients
  • empirical antibiotic therapy
  • empirical antifungal therapy
  • antibiotic resistance
  • gram-negative bacterial infection
  • home care
  • oral antibiotic therapy

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Castagnola, E., Mikulska, M., Barabino, P., Lorenzi, I., Haupt, R., & Viscoli, C. (2013). Current research in empirical therapy for febrile neutropenia in cancer patients: what should be necessary and what is going on. Expert Opinion on Emerging Drugs, 18(3), 263–278. https://doi.org/10.1517/14728214.2013.809419

How many times has this paper been cited?

12 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Elio Castagnola, Małgorzata Mikulska, Paola Barabino, Ines Lorenzi, Riccardo Haupt, Claudio Viscoli.

What is the DOI of this paper?

10.1517/14728214.2013.809419, permanently at https://doi.org/10.1517/14728214.2013.809419. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.